CDER Priorities: Initiatives and Innovation - Janet Woodcock M.d. Director, CDER, Fda

CDER Priorities: Initiatives and Innovation - Janet Woodcock M.d. Director, CDER, Fda is a 30-page legal document that was released by the U.S. Department of Health and Human Services - U.S. Food and Drug Administration and used nation-wide.

FAQ

Q: Who is Janet Woodcock?
A: Janet Woodcock is the Director of CDER, FDA.

Q: What is CDER?
A: CDER stands for Center for Drug Evaluation and Research.

Q: What are the priorities of CDER?
A: The priorities of CDER include initiatives and innovation in drug evaluation.

Q: What does CDER aim to achieve?
A: CDER aims to ensure the safety and efficacy of drugs for the American public.

Q: What is the role of FDA?
A: FDA, or the Food and Drug Administration, is responsible for protecting public health by regulating various products, including drugs.

Q: What is the role of CDER?
A: CDER is the branch of FDA that evaluates and approves drugs.

Q: Why is innovation important for CDER?
A: Innovation is important for CDER to keep up with advancements in drug development and bring new and effective treatments to patients.

Q: What are some initiatives of CDER?
A: Specific initiatives of CDER may vary, but they generally focus on improving drug safety and effectiveness, supporting innovation, and enhancing the regulatory process.